A series of new drugs that show progress in slowing down early-stage Alzheimer’s symptoms have emerged on the market. One such drug, Lecanemab — approved by the FDA in 2023 — is an infusion therapy that targets amyloid plaques in the brain, which are one of the...
The COVID-19 pandemic has caused disproportionate impacts across many populations. An MMWR published in July 2020 demonstrated that the burden of COVID-19 fell disproportionally on Black and Latinx patients, as well as homeless patients and those who were older than...
From the early days of the COVID-19 pandemic, it’s been clear that older adults who are infected face a greater risk of severe illness, hospitalization, or death than younger people. Eighty percent of COVID-19 deaths across the U.S. have been in adults 65 and older,...